April 15, 2024

Data Governance Committee Meeting 2024.4.15

April 15, 2024

Data Governance Committee Meeting

Attendees: Carol Levy, Daniel DeSalvo, Ann Mungmode, Holly Hardison, Saketh Rompicherla, Osagie Ebekozien, David Hansen, Nicole Rioles, David Ziemer, Grace Nelson, Kathryn Obrynba Isabel Reckson

Agenda:

1. Welcome
2. Data Governance Committee charter updates and co-chair update
3. Sponsored project preliminary results – total daily insulin analysis
4. Sponsored project update – T1D screening and monitoring QI and implementation
5. T2DX-QI industry partnership discussion

Data Governance Charter:

• Updated Purpose
• Updated Roles and Responsibilities
  • Co-Chair
  • Member
  • T1DX-QI (Coordinating Center)
• Addition of Data Governance Review Process
• Removal of Committee Member Names

Projects:

• Total Daily Insulin
  • Vertex on investigational approach
  • Estimate total daily insulin dose in children and adolescents
  • TDD increased by age and reached peak that coincided with puberty, earlier for female
  • MDI users has higher TDD than pump users
  • Vertex is very pleased with these results; these will go on to inform one or two manuscript opportunities in the future
  • This is a very impactful project
• T1D Screening and Monitoring
  • Examination of current processes and barriers
    • Communication of screening results
    • Follow up monitoring
  • Parallel process tracking
    • Qualtrics Survey and Smartsheet Reporting
  • ICD-10 diagnosis codes will become effective October 1, 2024 in the US:
    • A0 – Type 1 diabetes mellitus, presymptomatic, unspecified
    • A1 – Type 1 diabetes mellitus, presymptomatic, Stage 1
    • A2 – Type 1 diabetes mellitus, presymptomatic, Stage 2
    • FY 2025 IPPS Proposed Rule Home Page | CMSAnnouncement can be found in Table 6A
  • Also implementing the Consolidate Framework for Implementation Research to implement multiple focus groups throughout the project to learn centers’ experience implementing new processes and support expansion across the network
    • Help answer the question: how can other centers replicate this?
  • This project has implications for DGC as it expands the population in our EMR database to individuals who are screened and positive for autoantibodies but not yet confirmed T1D diagnosis
• Novo Nordisk Proposal
  • 2023 Standards of Care recommends consideration of GLP-1RA and SGLT2 for individuals with T2D
• T2DX-QI Industry Partners/Sponsor Brainstorming
  • Key T2DX-QI Elements
    • Patient Demographics
    • Device Use
    • Medications
    • BMI
    • Comorbidities
  • T2D Pump Study
  • T2D CGM Use
    • CGM use for patients not on insulin

Link to Recording:

https://us02web.zoom.us/rec/share/YdLhR1UnXbB8aGn4HwnvrIbA0YHpaLLluoPPvqaeoPJo-xmDpLihQIpd7iKUSFZn.8jVZMc658OX1E6ug

Passcode: 22M%N4yf